U.S. Markets closed

Verastem, Inc. (VSTM)


NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
3.53+0.02 (+0.57%)
At close: 4:00PM EDT
People also watch
STMLOMEDCERURGLSINFI

Verastem, Inc.

117 Kendrick Street
Suite 500
Needham, MA 02494
United States
781-292-4200
http://www.verastem.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees32

Key Executives

NameTitlePayExercisedAge
Mr. Robert Forrester LL.B.Chief Exec. Officer, Pres and Director858.69kN/A53
Mr. Daniel W. PatersonChief Operating Officer541.29kN/A56
Dr. Gregory I. Berk M.D.Sr. Advisor and Member of Clinical & Scientific Advisory Board565.33kN/A59
Mr. Richard H. Aldrich MbaFounder and ConsultantN/AN/A63
Dr. Robert A. Weinberg Ph.D.Co-Founder and Chair of Scientific Advisory BoardN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing drugs for the treatment of cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The company’s defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma. The company’s duvelisib is in Phase 3 randomized and two-arm trial for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, as well as completed the Phase 2 study for the treatment of patients with refractory indolent non-Hodgkin lymphoma. The company has license agreement with Infinity Pharmaceuticals, Inc.; The Scripps Research Institute; and Pfizer, Inc. Verastem, Inc. was founded in 2010 and is headquartered in Needham, Massachusetts.

Corporate Governance

Verastem, Inc.’s ISS Governance QualityScore as of July 1, 2017 is 9. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.